Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02923778 · ClinicalTrials.gov registry record · Phase 2

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

A Phase 2 study of Soft Tissue Sarcoma and Leiomyosarcoma, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 2
Development phase
40
Enrollment target
17
Study locations

NCT02923778 is a Phase 2 study of Soft Tissue Sarcoma and Leiomyosarcoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (49% lower). The trial reports 17 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02923778, a Phase 2 study of Soft Tissue Sarcoma and Leiomyosarcoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
17
Study locations

Study Summary

This phase II trial studies the side effects of talimogene laherparepvec and radiation therapy and to see how well they work in treating patients with newly diagnosed soft tissue sarcoma that can be removed by surgery (resectable). Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Radiation therapy uses high energy x-rays, photons. electrons, or protons to kill tumor cells and shrink tumors. Giving talimogene laherparepvec and radiation therapy may work better in treating patients with soft tissue sarcoma.

Conditions Studied

Soft Tissue Sarcoma Leiomyosarcoma Liposarcoma Undifferentiated Pleomorphic Sarcoma Sarcoma G2 Sarcoma G3 Soft Tissue Sarcoma of the Trunk and Extremities Stage I Soft Tissue Sarcoma AJCC v7 Stage II Soft Tissue Sarcoma AJCC v7

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Magnetic Resonance Imaging
  • PROCEDURE Biopsy Procedure
  • RADIATION Radiation Therapy
  • BIOLOGICAL Talimogene Laherparepvec

Study Locations (17)

Florida

  • Mayo Clinic in Florida - Jacksonville
  • University of Miami Miller School of Medicine-Sylvester Cancer Center - Miami
  • Moffitt Cancer Center - Tampa

Missouri

  • Siteman Cancer Center at West County Hospital - Creve Coeur
  • Washington University School of Medicine - St Louis
  • Siteman Cancer Center-South County - St Louis

California

  • City of Hope Comprehensive Cancer Center - Duarte
  • UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange

Arizona

  • Mayo Clinic Hospital in Arizona - Phoenix

Minnesota

  • Mayo Clinic in Rochester - Rochester

New Hampshire

  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center - Lebanon

New York

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone - New York

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2019-12-31
Est. Completion 2026-12-29
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02923778

The ClinicalTrials.gov registry entry for NCT02923778 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (49% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 9 conditions, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT02923778 reports 17 study locations spanning 12 distinct geographic areas - top geographies include Florida, Missouri, California.

Frequently Asked Questions

What is clinical trial NCT02923778 about?

NCT02923778 is a clinical study titled "Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery". This phase II trial studies the side effects of talimogene laherparepvec and radiation therapy and to see how well they work in treating patients with newly diagnosed soft tissue sarcoma that can be removed by surgery (resectable). Biological therapies, such as talimogene laherparepvec, use substanc...

What is the current status of trial NCT02923778?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2019-12-31. Estimated completion is 2026-12-29.

What conditions does trial NCT02923778 study?

This clinical trial studies the following conditions: Soft Tissue Sarcoma, Leiomyosarcoma, Liposarcoma, Undifferentiated Pleomorphic Sarcoma, Sarcoma G2.

What interventions are being tested in trial NCT02923778?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Biopsy Procedure (PROCEDURE), Radiation Therapy (RADIATION), Talimogene Laherparepvec (BIOLOGICAL).

Who is sponsoring clinical trial NCT02923778?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02923778 being conducted?

This trial has 17 study locations across Arizona, California, Florida, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Soft Tissue Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Soft Tissue Sarcoma

All registered trials for this condition

Leiomyosarcoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.